界定乳腺癌外科预防的终生风险阈值
该经济评价采用决策分析马尔可夫模型,从英国支付方视角比较风险降低性乳房切除术(RRM)与乳腺癌筛查联合药物预防的成本效果。模拟队列为30至60岁、终生乳腺癌风险17%至50%的女性。结果显示,在每质量调整生命年3万英镑支付意愿阈值下,30岁时终生风险达34%时RRM具成本效果;30至55岁且终生风险至少35%的女性中RRM具成本效果。
要点
- 30岁时终生乳腺癌风险达34%时,RRM在每QALY 3万英镑阈值下具成本效果。
- 30至55岁且终生风险至少35%的女性中,RRM具成本效果。
- 对终生风险35%及以上女性提供RRM,或可预防英国每年约11%的乳腺癌病例。
核心结论
- 在这项经济评价中,30至55岁且终生乳腺癌风险35%及以上的女性接受RRM似乎具成本效果。
- 这些结果可能对将RRM扩展至BRCA1/BRCA2/PALB2致病性变异携带者之外的人群具有重要临床意义。
- 未来需要开展评估这些女性对RRM的接受度、 uptake及长期结局的研究。
研究设计与样本
- 本研究为经济评价,采用决策分析马尔可夫模型比较RRM与乳腺癌筛查联合药物预防的成本效果。
- 研究视角为英国支付方,时间跨度至80岁终生 horizon。
- 模拟队列包括30至60岁、终生乳腺癌风险17%至50%的女性。
- 研究于2022年9月至2024年9月期间进行。
主要发现
- 在10万名30岁英国女性的模拟队列中,按每QALY 3万英镑支付意愿阈值,RRM在终生乳腺癌风险34%时具成本效果。
- 按每QALY 2万英镑支付意愿阈值,RRM具成本效果的终生风险阈值升至42%。
- 按每QALY 3万英镑阈值,35、40、45、50、55和60岁女性中RRM具成本效果的终生风险阈值分别为31%、29%、29%、32%、36%和42%。
- 总体而言,30至55岁且终生乳腺癌风险至少35%的女性接受RRM被认为具成本效果,概率敏感性分析中超过50%的模拟具成本效果。
- 对终生乳腺癌风险35%及以上女性提供RRM,可能预防英国女性每年58756例乳腺癌中的约6538例(95%CI 4454-7041),即约11%(95%CI 8%-12%)。
关键数值与推荐
- 增量成本效果比以每获得一个质量调整生命年(QALY)的增量成本计算,并与英国每QALY 2万英镑(27037美元)至3万英镑(40555美元)的支付意愿阈值比较。
- 在概率敏感性分析中,按每QALY 2万至3万英镑阈值,30岁接受RRM的女性中,终生风险35%者20.71%至59.96%的模拟具成本效果,40%者44.04%至81.29%的模拟具成本效果,50%者97.26%至99.35%的模拟具成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来需要开展评估这些女性对RRM的接受度、 uptake及长期结局的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Expanding access to genetic testing and availability of validated breast cancer (BC) risk prediction models are increasingly identifying women at elevated BC risk who do not carry high-penetrance BRCA1/BRCA2/PALB2 pathogenic variants. The precise BC risk threshold for offering risk-reducing mastectomy (RRM) for BC prevention is unknown. OBJECTIVE: To define the lifetime BC risk thresholds for RRM to be cost-effective compared with nonsurgical alternatives for BC prevention. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used a decision-analytic Markov model to compare the cost-effectiveness of RRM with BC screening and medical prevention in a simulated cohort. Extensive sensitivity analyses were performed. The study setting was from a UK payer perspective over a lifetime horizon until age 80 years. The simulated cohort included women aged 30 to 60 years at varying lifetime BC risks from 17% to 50%. The study was conducted between September 2022 and September 2024. EXPOSURES: Undergoing RRM or receiving risk-stratified BC screening with medical prevention (tamoxifen or anastrozole). MAIN OUTCOMES AND MEASURES: The incremental cost-effectiveness ratio was calculated as incremental cost per quality-adjusted life-year (QALY) gained and compared with the UK willingness-to-pay (WTP) threshold of £20 000 (US $27 037) to £30 000 (US $40 555) per QALY. BC cases prevented were estimated at the population level. RESULTS: In the simulated cohort of 100 000 thirty-year-old women in the UK, undergoing RRM became cost-effective at a 34% lifetime BC risk using the £30 000 (US $40 555) per QALY WTP threshold. This increased to a 42% lifetime BC risk using the £20 000 (US $27 037) per QALY WTP threshold. The identified lifetime BC risk thresholds for RRM to be cost-effective among women aged 35, 40, 45, 50, 55, and 60 years were 31%, 29%, 29%, 32%, 36%, and 42%, respectively, using the £30 000 (US $40 555) per QALY WTP threshold. Overall, undergoing RRM was deemed cost-effective for women aged 30 to 55 years with a lifetime BC risk of at least 35%, with more than 50% of simulations being cost-effective in probabilistic sensitivity analysis. Offering RRM for women with a lifetime BC risk of 35% or higher could potentially prevent approximately 6538 (95% CI, 4454-7041), or approximately 11% (95% CI, 8%-12%), of the 58 756 BC cases occurring annually in women in the UK. In the probabilistic sensitivity analysis, 20.71% to 59.96%, 44.04% to 81.29%, and 97.26% to 99.35% of simulations were cost-effective for women with 35%, 40%, and 50% lifetime BC-risk undergoing RRM at age 30 under the £20 000 to £30 000 per QALY WTP threshold, respectively. CONCLUSIONS AND RELEVANCE: In this economic evaluation, undergoing RRM appears cost-effective for women aged 30 to 55 years with a lifetime BC risk of 35% or higher. These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted.
引用
- Wei X, Mansour L, Oxley S, et al. Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention. JAMA Oncol. 2025. PMID: 40705362. doi:10.1001/jamaoncol.2025.2203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。